Skip to main content

Table 7 Postoperative morbidity and mortality

From: Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy

 

Neoadjuvant ( n= 80)

Adjuvant ( n= 90)

P

PHS (days)

11 (7–33)

11 (5–51)

0.920a

PHS with complications (days)

15

17

0.503b

PHS without complications (days)

11

11

0.972a

Patients with complications

15 (18.8%)

20 (22.2%)

0.704

Non-surgical complications

   

  Pneumonia

1 (1.3%)

3 (3.3%)

0.623

  Pleural effusion

0 (0.0%)

2 (2.2%)

0.499

  Gastrointestinal motility disorders

3 (3.8%)

3 (3.3%)

1.000

  Thrombosis

1 (1.3%)

1 (1.1%)

1.000

  Renal dysfunction

1 (1.3%)

1 (1.1%)

1.000

  Catheter-related sepsis

1 (1.3%)

0 (0.0%)

0.471

  Other (urinary, thrombocytopenia)

1 (1.3%)

4 (4.4%)

0.372

Surgical complications

   

  Anastomotic leakage

0 (0.0%)

2 (2.2%)

0.499

  Surgical site infection

5 (6.2%)

6 (6.7%)

1.000

  Postoperative hemorrhage

3 (3.8%)

1 (1.1%)

0.343

  Wound dehiscence

0 (0.0%)

2 (2.2%)

0.499

  Lymphorrhea

2 (2.5%)

1 (1.1%)

0.602

  Ileus

0 (0.0%)

1 (1.1%)

1.000

  Biliary fistula

1 (1.3%)

0 (0.0%)

0.471

  1. PHS postoperative hospital stay. aStatistical analyses by the Mann–Whitney U test due to non-normal distribution in one or both groups; bstatistical analyses by the Student’s t test due to a normal distribution in both groups.